West Pharmaceutical Services (WST) late Friday said in a regulatory filing it authorized the repurchase of up to 550,000 of its common shares from time to time.
The new stock buyback program is expected to run through Dec. 31, 2025, and will replace the company's existing program scheduled to expire at the end of the current year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments